Literature DB >> 28426852

An Outbreak of Endogenous Fungal Endophthalmitis Among Intravenous Drug Abusers in New England.

Aubrey R Tirpack1, Jay S Duker1, Caroline R Baumal1.   

Abstract

Importance: Intravenous drug abuse (IVDA) is a known risk factor for endogenous fungal endophthalmitis (EFE), a severe intraocular infection caused by hematogenous seeding of mycotic organisms to the eye. Reporting significant increases in heroin-related deaths since 2014, the New England region is in the midst of an opioid crisis that has led to a substantial increase in patients at risk for this vision-threatening disease. Objective: To present an update on characteristics, management, and visual outcomes in patients with EFE. Design, Setting, and Participants: Medical records review was initiated on July 1, 2016, evaluating all patients with EFE referred to New England Eye Center at Tufts Medical Center, a tertiary care ophthalmology practice distributed throughout Massachusetts, from May 1, 2014, to May 1, 2016. Patients with a history of IVDA and culture-proven or clinical evidence of fungal endophthalmitis were included. Exposures: Intravenous drug use. Main Outcomes and Measures: Patient demographics, comorbidities, presenting symptoms and vision, vitreoretinal findings, treatment regimens, culture data, and final visual acuities.
Results: Ten patients (5 women) with IVDA-related EFE were identified between May 1, 2014, and May 1, 2016-an increase from 3 patients treated from May 2012 to April 2014. The mean (SD) patient age was 34 (11) years (range, 24-60 years). Presenting visual acuities ranged from 20/25 to hand motion. The most common presenting symptoms were floaters (n = 8), reduced vision (n = 6), and pain (n = 5). Initial treatment included systemic antifungals in all patients and intravitreal antifungals in 9 eyes. Five patients required pars plana vitrectomy for worsening vitritis. The most commonly isolated pathogen was Candida albicans in 20% of the patients. Final visual acuity ranged from 20/40 to 20/300. Conclusions and Relevance: The data provided in this report suggest that EFE represents severe end organ damage associated with IVDA and portends poor visual outcomes. Health care professionals must maintain a high suspicion for EFE, as patients are typically ambulatory on presentation without systemic signs of infection.

Entities:  

Mesh:

Year:  2017        PMID: 28426852      PMCID: PMC5540046          DOI: 10.1001/jamaophthalmol.2017.0650

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN: 2168-6165            Impact factor:   7.389


  27 in total

Review 1.  Endogenous bacterial and fungal endophthalmitis.

Authors:  Stephen R Smith; Arnold J Kroll; Peter L Lou; Edward A Ryan
Journal:  Int Ophthalmol Clin       Date:  2007

Review 2.  Substance abuse, HIV-1 and hepatitis.

Authors:  Nirzari Parikh; Michael R Nonnemacher; Vanessa Pirrone; Timothy Block; Anand Mehta; Brian Wigdahl
Journal:  Curr HIV Res       Date:  2012-10       Impact factor: 1.581

3.  Possible role of preserved lemon juice in the epidemiology of candida endophthalmitis in heroin addicts.

Authors:  G S Shankland; M D Richardson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-01       Impact factor: 3.267

4.  Endogenous fungal endophthalmitis: causative organisms, management strategies, and visual acuity outcomes.

Authors:  Ahila Lingappan; Charles C Wykoff; Thomas A Albini; Darlene Miller; Avinash Pathengay; Janet L Davis; Harry W Flynn
Journal:  Am J Ophthalmol       Date:  2011-09-13       Impact factor: 5.258

Review 5.  Treatment outcomes of endogenous fungal endophthalmitis.

Authors:  W E Smiddy
Journal:  Curr Opin Ophthalmol       Date:  1998-06       Impact factor: 3.761

6.  Candida endophthalmitis after intravenous drug abuse.

Authors:  G L Aguilar; M S Blumenkrantz; P R Egbert; J P McCulley
Journal:  Arch Ophthalmol       Date:  1979-01

7.  Candida albicans endophthalmitis in brown heroin addicts: response to early vitrectomy preceded and followed by antifungal therapy.

Authors:  C Martínez-Vázquez; J Fernández-Ulloa; J Bordón; B Sopeña; J de la Fuente; A Ocampo; M Rubianes
Journal:  Clin Infect Dis       Date:  1998-11       Impact factor: 9.079

Review 8.  Voriconazole in the treatment of fungal eye infections: a review of current literature.

Authors:  S M Hariprasad; W F Mieler; T K Lin; W E Sponsel; J R Graybill
Journal:  Br J Ophthalmol       Date:  2008-07       Impact factor: 4.638

9.  Study of ocular candidiasis during nine-year period.

Authors:  Hiroki Tanaka; Kyoko Ishida; Wataru Yamada; Takashi Nishida; Kiyofumi Mochizuki; Hideaki Kawakami
Journal:  J Infect Chemother       Date:  2016-01-15       Impact factor: 2.211

10.  Experimental hematogenous endophthalmitis caused by Candida albicans.

Authors:  J E Edwards; J Z Montgomerie; R Y Foos; V K Shaw; L B Guze
Journal:  J Infect Dis       Date:  1975-06       Impact factor: 5.226

View more
  12 in total

1.  National emergency department trends for endogenous endophthalmitis: an increasing public health challenge.

Authors:  Loka Thangamathesvaran; Joseph K Canner; Adrienne W Scott; Fasika A Woreta; Mark P Breazzano
Journal:  Eye (Lond)       Date:  2022-04-29       Impact factor: 3.775

2.  The microbiological spectrum, antimicrobial resistance pattern, and visual outcomes of endogenous endophthalmitis in West Virginia 2009-2019.

Authors:  Chang Sup Lee; Jeffrey Desilets; Wei Fang; David M Hinkle
Journal:  Int Ophthalmol       Date:  2022-05-23       Impact factor: 2.029

3.  Endogenous Fungal Endophthalmitis: Causative Organisms, Treatments, and Visual Outcomes.

Authors:  Kuan-Jen Chen; Ming-Hui Sun; Yen-Po Chen; Yi-Hsing Chen; Nan-Kai Wang; Laura Liu; An-Ning Chao; Wei-Chi Wu; Yih-Shiou Hwang; Chi-Chun Lai
Journal:  J Fungi (Basel)       Date:  2022-06-16

Review 4.  Endophthalmitis: Then and Now.

Authors:  Nidhi Relhan; Richard K Forster; Harry W Flynn
Journal:  Am J Ophthalmol       Date:  2017-12-05       Impact factor: 5.258

Review 5.  Endogenous Endophthalmitis-The Clinical Significance of the Primary Source of Infection.

Authors:  Małgorzata Gajdzis; Kornelia Figuła; Joanna Kamińska; Radosław Kaczmarek
Journal:  J Clin Med       Date:  2022-02-23       Impact factor: 4.241

6.  The Incidence of Ocular Complications in Candidemic Patients and Implications for the Practice of Routine 
Eye Exams.

Authors:  Molly Hillenbrand; Angelico Mendy; Kavya Patel; Racheal Wilkinson; Siyun Liao; Jamie Robertson; Senu Apewokin
Journal:  Open Forum Infect Dis       Date:  2022-03-19       Impact factor: 3.835

Review 7.  Practical Guidance for Clinical Microbiology Laboratories: Diagnosis of Ocular Infections.

Authors:  Sixto M Leal; Kyle G Rodino; W Craig Fowler; Peter H Gilligan
Journal:  Clin Microbiol Rev       Date:  2021-06-02       Impact factor: 50.129

Review 8.  Mitigation of IV Abuse Through the Use of Abuse-Deterrent Opioid Formulations: An Overview of Current Technologies.

Authors:  Richard L Rauck
Journal:  Pain Pract       Date:  2019-02-28       Impact factor: 3.183

9.  Endogenous Endophthalmitis: yield of the diagnostic evaluation.

Authors:  Kathleen A Regan; Nila S Radhakrishnan; Jon D Hammer; Benjamin D Wilson; Lara Beth Gadkowski; Siva S R Iyer
Journal:  BMC Ophthalmol       Date:  2020-04-07       Impact factor: 2.209

10.  Sequential endogenous endophthalmitis, fungal keratitis, bacteremia and vertebral osteomyelitis in a person who injects drugs.

Authors:  Chad Y Lewis; Michael E Zegans; Nikhil N Batra; Kelsey L Jordan
Journal:  Am J Ophthalmol Case Rep       Date:  2021-06-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.